Sanguina Raises $2.8 Million in Series A Funding

Sanguina Inc. is $2.8 million richer, having completed a Series A funding round led by Veritus Holdings with participation from George Hornig of The Seed Lab. The funding will be used to accelerate the development and expansion of the firm’s blood health management digital and at-home-based platforms.

“We are thrilled to have secured this funding to further our mission of providing accessible tools for managing wellness and chronic conditions,” Sanguina Co-Founder/CEO Erika Tyburski said. “This investment will enable us to enhance our technology and platforms, bringing us closer to our vision of becoming a leading provider of home-based testing solutions.”
 
Sanguina is developing a platform of accessible tools for diagnosing, monitoring, and managing wellness and chronic conditions from home. The company was founded in 2019 as a spin-off from the Georgia Institute of Technology, Emory University, Children’s Healthcare of Atlanta, and the Centers for Disease Control and Prevention (CDC).
 
Hornig and Stephen Ippolito (Veritus Holdings) join Forbes 30u30 inventors and Sanguina co-founders Tyburski and Rob Mannino, Ph.D., and world-renowned hematologist, Wilbur Lam, M.D., Ph.D., on a board with knowledge spanning decades in the healthcare, consumer behavior, consumer experience, and financial services industries.
 
Sanguina’s flagship product, the AnemoCheck app, is a digital health platform that estimates hemoglobin levels and aids users in managing anemia. In addition to the app, Sanguina boasts a U.S. Food and Drug Administration-cleared point-of-care test, which the company plans to expand for home use later this year. Anemia, characterized by low hemoglobin levels, affects more than 1.6 billion individuals annually and has always been a marker of both illness and wellness, as it coexists with many chronic diseases and can guide treatment regimens. In June, two large, independent peer-reviewed published studies featured in the Annals of Internal Medicine and Journal of the American Medical Association revealed that anemia is a chronic problem for very large categories of Americans, ranging from those taking daily aspirin to women and girls who have iron deficiency from a variety of conditions. Additionally, clinical hematologists reviewed several studies on anemia and reveal that chronic health inequity has caused many women and minorities to normalize their anemia.
 
With advancements in home testing and artificial intelligence, the management of anemia and other chronic conditions is moving towards preventive and personalized medicine. The Series A funding round will enable Sanguina to enhance its existing product suite with artificial intelligence and machine learning models, improving utility, performance, and accessibility. Furthermore, this funding will pave the way for introducing new biomarkers and indications, including home-based testing for circulation, dehydration, for management of other chronic diseases.
 
With the successful launch of anemia management through the AnemoCheck app and point-of-care test, Sanguina has taken a major stride towards revolutionizing home-based testing and personalized disease management.
 
Sanguina Inc. is a biotech company that is advancing accessible digital and at-home health platforms for rapid home-based testing and disease management. The company aims to empower individuals by providing solutions for diagnosing, monitoring, and managing wellness and chronic conditions.